Treatments for Bowel Diseases to Be Focus at New GeneThera Lab Facility

Treatments for Bowel Diseases to Be Focus at New GeneThera Lab Facility
Westminster, Colorado based GeneThera Inc., a biotechnology company specializing in zoonotic diseases that can afflict both animals and people, recently announced it will have a new laboratory facility operational this spring. The facility will help the development of therapies for conditions such as Crohn's disease. "This is an important step towards expanding our molecular robotics and DNA therapeutic vaccine platforms," said Tony Milici, M.D., Ph.D., founder and CEO of GeneThera, in a press release. GeneThera's plan is to move into the new laboratory once renovation is complete. The anticipated move-in day is March 31. The 8,000-square-foot facility will have a fully integrated molecular robotics laboratory housing GeneThera IRSA robotic equipment for different tests, including Crohn's disease, through a highly sensitive detection capability for Mycobacterium Para tuberculosis. "In addition," said Milici, said, an expert in molecular biology, "we will have a state-of-the-art DNA vaccine laboratory fully dedicated to the development of Johne's and Crohn's disease therapeutic vaccines." While most people are aware of Crohn's disease -- a severe, devastating, and potentially lethal chronic inflammatory disorder of the human intestine -- and may know someone who suffers from it, Johne's disease (JD) has a much lower public profile, although many believe there is an important link between the two diseases. Johne's disease, an incurable chronic granulomatous inflammatory intestinal disorder, is found worldwide in both domestic and wild animals, and its prevalence in dairy cattle, sheep, and goats is a particular public health concern. Johne's is named for the German veterinarian who first described it in a dairy cow in 1865. Because it is caused by infect
Subscribe or to access all post and page content.